Olaparib is a United States Food and Drug Administration (FDA)-approved dual inhibitor of poly [ADP-ribose] polymerase 1 (PARP-1) and PARP-2 for the treatment of advanced ovarian and breast cancers. Here, PARP2 is linked to breast carcinoma.